Anne Pinot-Monange
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anne Pinot-Monange has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Sophie Gremeau
CHU Clermont-Ferrand, ART Department "AMP, CECOS", Clermont-Ferrand, France
1 shared publication - Aurélie Comptour
CIC 1405 CRECHE Unit, INSERM, Obstetrics and Gynaecology Department, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France
1 shared publication - Bruno Pereira
DRCI, Unité de Biostatistiques, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France
1 shared publication - Michel Canis
Department of Obstetrics Gynecology and Reproductive Medicine, CHU Clermont Ferrand, Clermont Ferrand, France
1 shared publication - Nicolas Bourdel
EnCoV, Institut Pascal, UMR 6602 CNRS/Université Clermont-Auvergne, Clermont-Ferrand, France; Department of Clinical Research and Innovation, University Hospital Clermont-Ferrand, 63000 Clermont Ferrand, France; Department of Gynecological Surgery, Clermont-Ferrand, France
1 shared publication - Pauline Chauvet
UMR 6602 CNRS, SIGMA Clermont, pôle FEE, EnCoV, service de gynécologie-obstétrique, université Clermont-Auvergne, Institut Pascal, CHU Estaing, 63000 Clermont-Ferrand, France
1 shared publication
Latest Publications
- Open Access
- 13 April 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (4) , 508
Repetitive Transcranial Magnetic Stimulation Therapy (rTMS) for Endometriosis Patients with Refractory Pelvic Chronic Pain: A Pilot Study
Endometriosis concerns more than 10% of women of reproductive age, frequently leading to chronic pelvic pain. Repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex (M1) induces an analgesic effect. This effect on chronic pelvic pain is yet to be evaluated. The objective of this study was to assess the feasibility and effect of rTMS to reduce pain and improve quality of life (QoL) in patients with chronic pelvic pain due to endometriosis. This pilot, open-labelled prospective trial examined treatment by neuronavigated rTMS over M1, one session per day for 5 consecutive days. Each session consisted of 1.500 pulses at 10 Hz. We assessed tolerance, pain change and QoL until 4 weeks post treatment with a primary endpoint at day 8. Twelve women were included. No patients experienced serious adverse effects or a significant increase in pain. Nine women reported improvement on the Patient Global Impression of Change with a reduction in both pain intensity and pain interference (5.1 ± 1.4 vs. 4.1 ± 1.6, p = 0.01 and 6.2 ± 2.1 vs. 4.2 ± 1.5, p = 0.004, respectively). rTMS appears well tolerated and might be of interest for patients suffering from chronic pelvic pain for whom other treatments have failed. A randomized controlled trial is mandatory before proposing such treatment.
- 13 April 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (4) , 508
Open AccessRepetitive Transcranial Magnetic Stimulation Therapy (rTMS) for Endometriosis Patients with Refractory Pelvic Chronic Pain: A Pilot Study
Endometriosis concerns more than 10% of women of reproductive age, frequently leading to chronic pelvic pain. Repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex (M1) induces an analgesic effect. This effect on chronic pelvic pain is yet to be evaluated. The objective of this study was to assess the feasibility and effect of rTMS to reduce pain and improve quality of life (QoL) in patients with chronic pelvic pain due to endometriosis. This pilot, open-labelled prospective trial examined treatment by neuronavigated rTMS over M1, one session per day for 5 consecutive days. Each session consisted of 1.500 pulses at 10 Hz. We assessed tolerance, pain change and QoL until 4 weeks post treatment with a primary endpoint at day 8. Twelve women were included. No patients experienced serious adverse effects or a significant increase in pain. Nine women reported improvement on the Patient Global Impression of Change with a reduction in both pain intensity and pain interference (5.1 ± 1.4 vs. 4.1 ± 1.6, p = 0.01 and 6.2 ± 2.1 vs. 4.2 ± 1.5, p = 0.004, respectively). rTMS appears well tolerated and might be of interest for patients suffering from chronic pelvic pain for whom other treatments have failed. A randomized controlled trial is mandatory before proposing such treatment.